Please ensure Javascript is enabled for purposes of website accessibility

J&J's Public Image in the Red

By Brian Orelli, PhD – Updated Nov 11, 2016 at 6:32PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Suing a charity? What was it thinking?

Johnson & Johnson's (NYSE:JNJ) lawsuit against the American Red Cross was a no-win situation for the perennial American health-care company.

Let me back up a moment. J&J had sued the American Red Cross for licensing its red cross symbol -- you know, the red one on the white background, the one the charity organization has used for over 100 years -- to a few companies in exchange for a royalty payment on sales of those companies' health-care products. The claim was trademark infringement.

That may sound crazy to you, but trademarks are a big deal to companies and are vigorously defended. If the words or symbol become generic enough, such as "Kleenex" used as a substitute for facial tissue, then the company holding the trademark, e.g. Kimberly-Clark (NYSE:KMB), can lose the rights associated with it. (Note that Kimberly-Clark still holds that particular trademark.)

Back to our story.

Yesterday's announcement that the judge was throwing out much of the case might have been the best outcome for Johnson & Johnson. The company was really between a rock and a hard place here.

On the one hand, trademark infringement -- both organizations use a red cross on a white background -- is a serious issue and could cost Johnson & Johnson sales. Its products compete against the American Red Cross-licensed products on shelves of retailers such as Wal-Mart (NYSE:WMT), Target (NYSE:TGT), and CVS Caremark (NYSE:CVS).

On the other hand, how could it sue a beloved charity and not end up with a permanent scar to its public image?

The judge threw out much of the suit against the American Red Cross, saying the charity is free to use and license the symbol it's been using for over a century. After all, both various Geneva Conventions and the U.S. Congress had authorized it, the judge noted. The only part of the suit remaining is J&J's claim that the charity interfered with its contracts with privately held companies, Water-Jel and First Aid Only. Four companies that have licensing agreements with the charity are also countersuing Johnson & Johnson.

Really, this may have been the best outcome for Johnson & Johnson. It got to show its legal muscle to the charity, which might cause the latter to tread lightly in future licensing deals. But J&J didn't actually win anything, so it doesn't come across looking as much a bully as it would if it had won.

Perhaps that was the company's strategy all along?

More Foolishness on the company that's just slightly younger than dirt:

None

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$166.72 (0.33%) $0.54
Walmart Stock Quote
Walmart
WMT
$130.06 (-2.50%) $-3.33
Target Corporation Stock Quote
Target Corporation
TGT
$152.61 (-0.23%) $0.35
Kimberly-Clark Corporation Stock Quote
Kimberly-Clark Corporation
KMB
$120.29 (-0.35%) $0.42
CVS Health Corporation Stock Quote
CVS Health Corporation
CVS
$98.35 (-1.48%) $-1.48

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.